Chiral drugs

Class of drugs

Chemical compounds that come as mirror-image pairs are referred to by chemists as chiral or handed molecules.[1] Each twin is called an enantiomer. Drugs that exhibit handedness are referred to as chiral drugs. Chiral drugs that are equimolar (1:1) mixture of enantiomers are called racemic drugs and these are obviously devoid of optical rotation. The most commonly encountered stereogenic unit,[2] that confers chirality to drug molecules are stereogenic center. Stereogenic center can be due to the presence of tetrahedral tetra coordinate atoms (C,N,P) and pyramidal tricoordinate atoms (N,S). The word chiral describes the three-dimensional architecture of the molecule and does not reveal the stereochemical composition. Hence "chiral drug" does not say whether the drug is racemic (racemic drug), single enantiomer (chiral specific drug) or some other combination of stereoisomers. To resolve this issue Joseph Gal introduced a new term called unichiral.[3][4] Unichiral indicates that the stereochemical composition of a chiral drug is homogenous consisting of a single enantiomer.

Many medicinal agents important to life are combinations of mirror-image twins. Despite the close resemblance of such twins, the differences in their biological properties can be profound. In other words, the component enantiomers of a racemic chiral drug may differ wildly in their pharmacokinetic, pharmacodynamic profile.[5][6][7][8] The tragedy of thalidomide illustrates the potential for extreme consequences resulting from the administration of a racemate drug that exhibits multiple effects attributable to individual enantiomers.[9] With the advancements in chiral technology and the increased awareness about three-dimensional consequences of drug action and disposition emerged specialized field "chiral pharmacology". Simultaneously the chirality nomenclature system also evolved. A brief overview of chirality history and terminology/descriptors is given below. A detailed chirality timeline is not the focus of this article.

## Chirality: history overview

[edit]

Louis Pasteur - pioneering stereochemist

Chirality can be traced back to 1812, when physicist Jean-Baptiste Biot found out about a phenomenon called "optical activity."[10] Louis Pasteur, a famous student of Biot's, made a series of observations that led him to suggest that the optical activity of some substances is caused by their molecular asymmetry, which makes nonsuperimposable mirror-images. In 1848, Pasteur grew two different kinds of crystals from the racemic sodium ammonium salt of tartaric acid. He was the first person to separate enantiomeric crystals by hand.[11] In fact Pasteur laid the foundations of stereochemistry and chirality.

In 1874, Jacobus Henricus van 't Hoff came up with the idea of an asymmetric carbon atom. He said that all optically active carbon compounds have an asymmetric carbon atom.[12] In the same year, Joseph Achille Le Bel only used asymmetry arguments and talked about the asymmetry of the molecules as a whole instead of the asymmetry of each carbon atom.[13] So, Le Bel's idea could be seen as the general theory of stereoisomerism, while van 't Hoff's could be seen as a special case (restricted to tetrahedral carbon).

Soon, scientists started to look into what chiral compounds meant for living things. In 1903, Cushny was the first person to show that enantiomers of a chiral molecule have different biological effects.[14] Lord Kelvin used the word "chiral" for the first time in 1904.[15]

## Chirality: terminology/descriptors

[edit]

This is to give an overview of the evolving chirality nomenclature system commonly employed to distinguish enantiomers of a chiral drug. In the beginning, enantiomers were distinguished based on their ability to rotate the plane of plane-polarized light. The enantiomer that rotates the plane-polarized light to the right is named "dextro-rotatory", abbreviated as "dextro" or "d" and the counterpart as "levo" or "l". A racemic mixture is denoted as "(±)", "rac", or "dl". Now the d/l system of naming based on optical rotation is falling into disuse.

Later, the Fischer convention[16][17] was introduced to specify the configuration of a stereogenic center and uses the symbols D and L. The use of capital letters is to differentiate from the "d" / "l" notation (optical descriptor) described earlier. In this system, the enantiomers are named with reference to D- and L-glyceraldehyde which is taken as the standard for comparison. The structure of the chiral molecule should be represented in the Fischer projection formula. If the hydroxyl group attached to the highest chiral carbon is on the right-hand side it is referred to as D-series and if on the left-hand side it is called L-series. This nomenclature system has also become obsolete. But D-/L-system of naming is still employed to designate the configuration of amino acids and sugars. In general the D/L system of nomenclature is superseded by the Cahn-Ingold-Prelog (CIP) rule to describe the configuration of a stereogenic/chiral center.

In the CIP or R/S convention, or sequence rule, the configuration, spatial arrangements of ligands/substituents around a chiral center, is labeled as either "R" or "S".[18][2] This convention is now almost worldwide in use and become a part of the IUPAC (International Union of Pure and Applied Chemistry) rules of nomenclature. In this approach: identify the chiral center, label the four atoms directly attached to the stereogenic center in question, assign priorities according to the sequence rule ( from 1 to 4), rotate the molecule until the lowest priority (number 4) substituent is away from the observer/viewer, draw a curve from number 1 to number 2 to number 3 substituent. If the curve is clockwise, the chiral center is of R-absolute configuration, "R" (Latin, rectus = right). If the curve is counterclockwise, the chiral center is of S-absolute configuration, "S" (Latin, sinister = left). Refer to figure, the Cahn-Ingold-Prelog rule.

The Cahn-Ingold-Prelog rule

An overview of the nomenclature system is presented in the table below.

Chirality descriptor
(used as prefix) | Description  | Comments

|
|

(+)- / dextro-/ d- | Optical rotation signs; does not reflect the configuration  | d; Obsolete terms/falling in disuse
(-)- / levo- | Optical rotation signs; does not reflect the configuration  | l; Obsolete terms/falling in disuse
(±)- / rac- / dl- | Racemate or racemic mixture is an equimolar (1:1) mixture of enantiomers; corresponds to the enantiomeric excess of 0%.  | dl; Obsolete terms/falling in disuse
D-  | Relative configuration with respect to D-glyceraldehyde; referred to as Fischer convention  | \-
L-  | Relative configuration with respect to L-glyceraldehyde; referred to as Fischer convention  | \-
R-  | Latin: rectus = right; absolute configuration as per Cahn-Ingold-Prelog rule/sequence rule  | \-
S-  | Latin: sinister = left; absolute configuration as per Cahn-Ingold-Prelog rule/Sequence rule  | \-

## Racemic drugs

[edit]

For many years scientists in drug development have been blind to the three-dimensional consequences of stereochemistry, chiefly due to the lack of technology for making enantioselective investigations. Besides the thalidomide tragedy, another event that raised the importance of issues of stereochemistry in drug research and development was the publication of a manuscript in 1984 entitled, "Stereochemistry, a basis of sophisticated nonsense in pharmacokinetics and clinical pharmacology" by Ariëns.[19] This article, and the series of articles that followed, criticized the practice of conducting pharmacokinetic and pharmacodynamic studies on racemic drugs and ignoring the separate contributions of the individual enantiomers.[20][21][22][23][24][25] These papers have served to crystallize some of the important issues surrounding racemic drugs and stimulated much discussion in industry, government and academia.

### Chiral pharmacology

[edit]

As a result of these criticisms and the renewed awareness of the three-dimensional effects of drug action fueled by the exponential explosion of chiral technology emerged the new area "stereo-pharmacology". A more specific term is "chiral pharmacology", a phrase popularized by John Caldwell.[26] This field has grown itself into a specialized discipline concerned with the three-dimensional aspects of drug action and disposition. This approach essentially views each version of the chiral twins as separate chemical species. To express the pharmacological activities of each of the chiral twins two technical terms have been coined, eutomer and distomer.[27] The member of the chiral twin that has greater physiological activity is referred to as the eutomer and the other one with lesser activity is referred to as distomer. It is generally understood that this reference is necessarily to a single activity being studied. The eutomer for one effect may well be the distomer when another is studied. The eutomer/distomer ratio is called the eudysmic ratio.[28]

### Bio-environment and chiral twins

[edit]

The behavior of the chiral twins depends mainly on the nature of the environment (achiral/chiral) in which they are present. An achiral environment does not differentiate the molecular twins whereas a chiral environment does distinguish the left-handed version from the right-handed version. Human body, a classic bio-environment, is inherently handed as it is filled with chiral discriminators like amino acids, enzymes, carbohydrates, lipids, nucleic acids, etc. Hence when a racemic therapeutic gets exposed to biological system the component enantiomers will be acted upon stereoselectively.[29] For drugs, chiral discrimination can take place either in the pharmacokinetic or pharmacodynamic phase.

### Chiral discrimination

[edit]

Easson and Stedman[30] (1933) advanced a drug-receptor interaction model to account for the differential pharmacodynamic activity between enantiomeric pairs. In this model the more active enantiomer (the eutomer) take part in a minimum of three simultaneous intermolecular interactions with the receptor surface (good fit), Figure. A., where as the less active enantiomer (distomer) interacts at two sites only (bad fit), Figure B. [Refer image for Figure: Easson-Stedman model]. Thus the "fit" of the individual enantiomers to the receptor site differs, as does the energy of interaction. This is a simplistic model but used to explain the biological discrimination between enantiomeric pairs.

Easson-Stedman model

In reality the drug-receptor interaction is not that simple, but this view of such complex phenomenon has provided major insights into the mechanism of action of drugs.

### Pharmacodynamic considerations

[edit]

Racemic drugs are not drug combinations in the accepted sense of two or more co-formulated therapeutic agents, but combinations of isomeric substances whose pharmacological activity may reside predominantly in one specific enantiomeric form. In case of stereoselectivity in action only one of the components in the racemic mixture is truly active. The other isomer, the distomer, should be regarded as impurity or isomeric ballast,[31] a term coined by Ariëns, not contributing to the effects aimed at. In contrast to the pharmacokinetic properties of an enantiomeric pair, differences in pharmacodynamic activity tend to be more obvious. There is a wide spectrum of possibilities of distomer actions, many of which are confirmed experimentally.[32][33][34] Selected examples of the distomer actions (viz. equipotent, less active, inactive, antagonistic, chiral inversion) are presented in the table below.

Chiral drug  | Stereogenic
center(s)  | Therapeutic action  | Eutomer  | Distomer  | Distomer action  | Reference

|
|
|
|
|
|

promethazine | 1  | Antihistaminic  | (R)-/(S)-  | \-  | Equipotent  | [35]
Salbutamol | 1  | Bronchodilator  | (R)-  | (S)-  | Less active; no serious side-effects  | [5]
Propranolol | 1  | Antihypertensive  | (S)-  | (R)-  | Inactive; half placebo  | [36][37]
Indacrinone | 1  | Diuretic  | (R)-  | (S)-  | Antagonizes side effect of the eutomer  | [38]
Propoxyphene | 2  | Analgesic; (Dexpropoxyphene)  | (2R),(3S)-  | (2S),(3R)-  | Independent therapeutic value  | [39]
Antitussive; (Levopropoxyphene)  | (2S),(3R)-  | (2R),(3S)-
Ibuprofen | 1  | Anti-inflammatory  | (S)-  | (R)-  | Chiral inversion (unidirectional; [(R)- to (S)-]  | [40]

### Drug toxicity

[edit]

Since there is a frequent large pharmacokinetic and pharmacodynamic differences between enantiomers of a chiral drug it is not surprising that enantiomers may result in stereoselective toxicity. They can reside in the pharmacologically active enantiomer (eutomer) or in the inactive one (distomer).[41][42][43] The toxicologic differences between enantiomers of have also been demonstrated. The following are examples of some of the chiral drugs where their toxic/undesirable side-effects dwell almost in the distomer. This would seem to be a clear cut case of going for a chiral switch.

#### Penicillamine

[edit]

D-(–)-(S)-Penicillamine
(antiarthritic)

L-(+)-(R)-Penicillamine
(toxic)

Penicillamine is a chiral drug with one chiral center and exists as a pair of enantiomers. (S)-penicillamine is the eutomer with the desired antiarthritic activity while the (R)-penicillamine is extremely toxic.[44]

#### Ketamine

[edit]

Ketamine enantiomers

Ketamine is a widely used anaesthetic agent. It is a chiral molecule that is administered as a racemate. Studies show that (S)-(+)-ketamine is the active anaesthetic and the undesired side-effects (hallucination and agitation) reside in the distomer, (R)-(-)-ketamine.[45][46][47]

#### Dopa

[edit]

Dopa enantiomers

The initial use of racemic dopa for the treatment of Parkinson's disease resulted in a number of adverse effects viz. nausea, vomiting, anorexia, involuntary movements and granulocytopenia. The use of L-dopa [the (S)-enantiomer] resulted in reducing the required dose, and adverse effects. The granulocytopenia was not observed with the single enantiomer.[48][49][50]

#### Ethambutol

[edit]

Ethambutol enantiomers

The antitubercular agent Ethambutol contains two constitutionally symmetrical stereogenic centers in its structure and exists in three stereoisomeric forms. An enantiomeric pair (S,S)- and (R,R)-ethambutol, along with the achiral stereoisomer called meso-form, it holds a diastereomeric relationship with the optically active stereoisomers. The activity of the drug resides in the (S,S)-enantiomer which is 500 and 12 fold more potent than the (R,R)-ethambutol and the meso-form. The drug had initially been introduced for clinical use as the racemate and was changed to the (S,S)-enantiomer, as a result of optic neuritis leading to blindness. Toxicity is related to both dose and duration of treatment. All the three stereoisomers were almost equipotent with respect to side effects. Hence the use of S,S)-enantiomer greatly enhanced the risk/benefit ratio.[51][52]

#### Thalidomide

[edit]

Thalidomide enantiomers

Thalidomide is a classical example highlighting the alleged role of chirality in drug toxicity. Thalidomide was a racemic therapeutic and prescribed to pregnant women to control nausea and vomiting. The drug was withdrawn from world market when it became evident that the use in pregnancy causes phocomelia (clinical conditions where babies are born with deformed hand and limbs). Later in late 1970s studies indicated that the (R)- enantiomer is an effective sedative, the (S)-enantiomer harbors teratogenic effect and causes fetal abnormalities.[53][54][55] Later studies established that under biological conditions the (R)-thalidomide, good partner, undergoes an in vivo metabolic inversion to the (S)-thalidomide, evil partner and vice versa. It is a bidirectional chiral inversion. Hence the argument that the thalidomide tragedy could have been avoided by using a single enantiomer is ambiguous and pointless.[56][57][58]

The salient features are presented in the table below.

Chiral drugs: Adverse effects residing in the distomer  Chiral drug | Chiral centers | Clinical effects

|
|

|  | Eutomer; Activity  | Distomer; Activity
Penicillamine  | 1  | (S)-; Antiarthritic  | (R)-; Mutagen
Ketamine  | 1  | (S)-; Anesthetic  | (R)-; Hallucinogen
Dopa  | 1  | (S)-; Antiparkinson  | (R)-; Granulocytopenia
Ethambutol  | 2  | (S,S)-; Tuberculostatic  | (R,R)-; and meso- form; Blindness
Thalidomide  | 1  | (R)-; Sedative  | (S)-; Teratogenic

## Unichiral drugs

[edit]

Main article: Enantiopure drug

Unichiral indicates configurationally homogeneous substance (i.e. made up of chiral molecules of one and the same configuration). Other commonly used synonyms are enantiopure drugs and enantiomerically pure drugs.

Monochiral drugs has also been suggested as another synonym,[59] although Professor Eliel, Wilen, and Gal expressed their deep concern over the misuse of the term "homochiral" in articles to denote enantiomerically pure drugs, which is incorrect.[60][61][62] Homochiral means objects or molecules of the same handedness. Hence should be used only for comparison of two or more objects of like "chirality". For instance, left hands of different individuals, or say R-naproxen and R-ibuprofen.

Globally drug companies and regulatory agencies have an inclination towards the development of unichiral drugs as a consequence of the increased understanding of the differing biological properties of individual enantiomers of a racemic therapeutics. Most of these unichiral drugs are the consequence of chiral switch approach. The table below list selected unichiral drugs used in drug therapy.

Unichiral drugs employed in drug therapy  Unichiral drugs  | Drug class/ Type of medication  | Therapeutic area

|
|

Esomeprazole | Proton pump inhibitor  | Gastroenterology
S-pantoprazole  | Proton pump inhibitor
Dexrabiprazole  | Proton pump inhibitor
Levosalbutamol | Bronchodilator  | Pulmonology
Levocetrizine | Antihistaminic
Levofloxacin | Antibacterial  | Infectious diseases
S-penicillamine  | Rheumatoid Arthritis  | Rheumatology / Pain/ Inflammation
S-etodolac  | NSAID
Dexketoprofen | NSAID
S-ketamine | Anesthetic  | Anesthesiology
Levobupivacaine | Local anesthetic
Levothyroxine | Anti-hypothyroidism  | Endocrinology
Levodopa | Anti-Parkinson  | Neuropsychiatry
S-amlodipine | Antianginal / Antihypertensive  | Cardiology
S-metoprolol  | Antihypertensive
S-atenolol  | Antihypertensive

A company may go in for developing a racemic drug against an enantiomer by providing adequate reasoning. The rationale why a company might pursue developing racemic drugs[63][64][65] could include expensive separation of enantiomers, eutomer racemizes in solution (e.g. oxazepam),[66] activities of the enantiomeric pair are different but supplementary, distomer is inactive, but separation is exorbitant. Insignificant/low toxicity of the distomer, high therapeutic index, mutually beneficial, pharmacological activities of both the enantiomers, and if the development of an enantiomer takes huge amount of time for a drug of emergency need e.g., cancer, AIDS, etc.

### Chiral purity

[edit]

Chiral purity is a measure of the purity of a chiral drug. Other synonyms employed include enantiomeric excess, enantiomer purity, enantiomeric purity, and optical purity. Optical purity is an obsolete term since today most of the chiral purity measurements are done using chromatographic techniques (not based on optical principles). Enantiomeric excess tells the extent (in %) to which the chiral substance contains one enantiomer over the other. For a racemic drug the enantiomeric excess will be 0%. There are number of chiral analysis tools such as polarimetry, NMR spectroscopy with the use of chiral shift reagents, chiral GC (gas chromatography), chiral HPLC (high performance liquid chromatography), chiral TLC (thin-layer chromatography)[67] and other chiral chromatographic techniques, that are employed to evaluate chiral purity.[68] Assessing the purity of a unichiral drug or enantiopure drug is of great importance from a drug safety and efficacy perspective.

## See also

[edit]

* Chirality (chemistry)
* Chiral switch
* Chiral analysis
* Chiral inversion
* Racemate
* Stereochemistry
* Chirality timeline

## References

[edit]

1. ^ Bassindale, A (1984). The Third Dimension in Organic Chemistry. New York: John Wiley, New York. ISBN 047190189X.
2. ^ a b Mislow, Kurt; Siegel, Jay (1984). "Stereoisomerism and local chirality". Journal of the American Chemical Society. 106 (11): 3319–3328\. Bibcode:1984JAChS.106.3319M. doi:10.1021/ja00323a043. ISSN 0002-7863.
3. ^ Gal, Joseph; Lindner, wolfgang (2006). "Chiral drugs from a historical point of view". In Francotte, Eric (ed.). Chirality in drug research. Germany: Wiley-VCH Verlag GmbH & Co. pp. 3–26\. ISBN 3-527-31076-2.
4. ^ Gal, J (1998). "Problems of stereochemical nomenclature and terminology. 1. The homochiral controversy. Its nature, origins, and a proposed solution". Enantiomer. 3: 263–273.
5. ^ a b Jamali, F.; Mehvar, R.; Pasutto, F.M. (1989). "Enantioselective Aspects of Drug Action and Disposition: Therapeutic Pitfalls". Journal of Pharmaceutical Sciences. 78 (9): 695–715\. doi:10.1002/jps.2600780902. ISSN 0022-3549. PMID 2685226.
6. ^ Williams, Kenneth M. (1991), Molecular Asymmetry and Its Pharmacological Consequences, Advances in Pharmacology, vol. 22, Elsevier, pp. 57–135, doi:10.1016/s1054-3589(08)60033-2, ISBN 978-0-12-032922-9, PMID 1958505, retrieved 2021-06-03
7. ^ Crossley, Roger (1992). "The relevance of chirality to the study of biological activity". Tetrahedron. 48 (38): 8155–8178\. doi:10.1016/s0040-4020(01)80486-5. ISSN 0040-4020.
8. ^ Gross, Michael (1990), Chapter 34. Significance of Drug Stereochemistry in Modern Pharmaceutical Research and Development, Annual Reports in Medicinal Chemistry, vol. 25, Elsevier, pp. 323–331, doi:10.1016/s0065-7743(08)61610-3, ISBN 978-0-12-040525-1, retrieved 2021-06-03
9. ^ Decamp, W (1989). "The FDA perspective on the development of stereoisomers". Chirality. 1 (1): 2–6\. doi:10.1002/chir.530010103. PMID 2642032.
10. ^ Biot, J.B. (1812). "The rotation of the axes of polarization of light by certain substances". Mém. Classe Sci. Math. Phys. Inst. Imperial France. II: 41–136.
11. ^ Pasteur, L. (1848). "Mémoire sur la relation qui peut exister entre la forme crystalline et la composition chimique, et sur la cause de la polarisation rotatoire" [Note on the relationship of crystalline form to chemical composition, and on the cause of rotatory polarization] (PDF). C. R. Hebd. Séances Acad. Sci. 26: 535–538.
12. ^ van't Hoff, J. H. (1874). "Proposal for the extension of current chemical structural formulas into space, together with related observation on the connection between optically active power and the chemical constitution of organic compounds". Arch. Neerl. Sci. Exacts Nat. (9): 445–454.
13. ^ Le Bel, J. A. (1874). "On the relations which exist between the atomic formulas of organic compounds and the rotatory power of their solutions". Bull. Soc. Chim. Fr. 22: 337–347.
14. ^ Cushny, Arthur R. (1903-11-02). "Atropine and the hyoscyamines-a study of the action of optical isomers". The Journal of Physiology. 30 (2): 176–194\. doi:10.1113/jphysiol.1903.sp000988. ISSN 0022-3751. PMC 1540678. PMID 16992694.
15. ^ Kelvin, Lord (W. Thomson) (1904), Baltimore Lectures on Molecular Dynamics and the Wave Theory of Light, C. J. Clay & Sons, London. The lectures were given in 1884 and 1893.
16. ^ Hartung, Walter H.; Andrako, John (1961). "Stereochemistry". Journal of Pharmaceutical Sciences. 50 (10): 805–818\. doi:10.1002/jps.2600501002. ISSN 0022-3549. PMID 14036070.
17. ^ Slocum, D. W.; Surgarman, D.; Tucker, S. P. (1971). "The two faces of D and L nomenclature". Journal of Chemical Education. 48 (9): 597. Bibcode:1971JChEd..48..597S. doi:10.1021/ed048p597. ISSN 0021-9584.
18. ^ Cahn, B. S.; lngold, C. K; Prelog, V (1956). "The specification of asymmetric configuration in organic chemistry". Experientia. 12 (3): 81–88\. doi:10.1007/BF02157171. S2CID 43026989.
19. ^ Ariens, E. J. (1984). "Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology". European Journal of Clinical Pharmacology. 26 (6): 663–668\. doi:10.1007/bf00541922. ISSN 0031-6970. PMID 6092093. S2CID 30916093.
20. ^ Ariëns, Everardus J. (1987). "Stereochemistry in the analysis of drug-action. Part II". Medicinal Research Reviews. 7 (3): 367–387\. doi:10.1002/med.2610070305. ISSN 0198-6325. PMID 3041134. S2CID 31403941.
21. ^ Ariëns, E. J. (1988). "Stereochemical implications of hybrid and pseudo-hybrid drugs. Part III". Medicinal Research Reviews. 8 (2): 309–320\. doi:10.1002/med.2610080206. ISSN 0198-6325. PMID 3288823. S2CID 33013615.
22. ^ Ariëns, E.J (1987). "Implications of the Neglect of Stereochemistry in Pharmacokinetics and Clinical Pharmacology". Br. J. Clin. Pharmacol. Ther. 21 (10): 827–829\. doi:10.1177/106002808702101013. PMID 3322758. S2CID 23007083.
23. ^ Ariëns, Everd J. (1987). "Implications of the Neglect of Stereochemistry in Pharmacokinetics and Clinical Pharmacology". Drug Intelligence & Clinical Pharmacy. 21 (10): 827–829\. doi:10.1177/106002808702101013. ISSN 0012-6578. PMID 3322758. S2CID 23007083.
24. ^ Ariëns, E. J. (1989). "Stereoselectivity in the Action of Drugs". Pharmacology & Toxicology. 64 (4): 319–320\. doi:10.1111/j.1600-0773.1989.tb00655.x. ISSN 0901-9928. PMID 2748538.
25. ^ Ariëns, E.J. (1986). "Chirality in bioactive agents and its pitfalls". Trends in Pharmacological Sciences. 7: 200–205\. doi:10.1016/0165-6147(86)90313-5. ISSN 0165-6147.
26. ^ Caldwell, John (1995). "Chiral Pharmacology and the regulation of new drugs". Chemistry and Industry. 6: 176–179.
27. ^ Pfeiffer, C. C. (1956-07-06). "Optical Isomerism and Pharmacological Action, a Generalization". Science. 124 (3210): 29–31\. Bibcode:1956Sci...124...29P. doi:10.1126/science.124.3210.29. ISSN 0036-8075. PMID 13337345.
28. ^ Ariëns, Everhardus J.; Wuis, Eveline W.; Veringa, Eric J. (1988). "Stereoselectivity of bioactive xenobiotics". Biochemical Pharmacology. 37 (1): 9–18\. doi:10.1016/0006-2952(88)90749-6. ISSN 0006-2952. PMID 3276322.
29. ^ Wainer, Irving W. (1992-09-01). "Three-dimensional view of pharmacology". American Journal of Health-System Pharmacy. 49 (9_Suppl): S4 – S8. doi:10.1093/ajhp/49.9_suppl_1.s4. ISSN 1079-2082. PMID 1530004.
30. ^ Easson, Leslie Hilton; Stedman, Edgar (1933-01-01). "Studies on the relationship between chemical constitution and physiological action". Biochemical Journal. 27 (4): 1257–1266\. doi:10.1042/bj0271257. ISSN 0306-3283. PMC 1253018. PMID 16745220.
31. ^ Drayer, Dennis E (1986). "Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: An overview". Clinical Pharmacology and Therapeutics. 40 (2): 125–133\. doi:10.1038/clpt.1986.150. ISSN 0009-9236. PMID 3731675. S2CID 33537650.
32. ^ Scott, Andrew K. (1990). "Stereoisomers in Clinical Pharmacology". Drug Information Journal. 24 (1): 121–123\. doi:10.1177/009286159002400123. ISSN 0092-8615. S2CID 72095771.
33. ^ Lehmann, Pedro A.F. (1986). "Stereoisomerism and drug action". Trends in Pharmacological Sciences. 7: 281–285\. doi:10.1016/0165-6147(86)90353-6. ISSN 0165-6147.
34. ^ ARIENS, E.J. (1990), "Racemic Therapeutics—Problems all Along the Line", Chirality in Drug Design and Synthesis, Elsevier, pp. 29–43, doi:10.1016/b978-0-12-136670-4.50008-4, ISBN 978-0-12-136670-4, retrieved 2021-06-03
35. ^ Hutt, A. J.; Tan, S. C. (1996). "Drug Chirality and its Clinical Significance". Drugs. 52 (Supplement 5): 1–12\. doi:10.2165/00003495-199600525-00003. ISSN 0012-6667. PMID 8922553. S2CID 41802235.
36. ^ Simonyi, Miklós (1984). "On chiral drug action". Medicinal Research Reviews. 4 (3): 359–413\. doi:10.1002/med.2610040304. ISSN 0198-6325. PMID 6087043. S2CID 38829275.
37. ^ Williams, Kenneth; Lee, Edmund (1985). "Importance of Drug Enantiomers in Clinical Pharmacology". Drugs. 30 (4): 333–354\. doi:10.2165/00003495-198530040-00003. ISSN 0012-6667. PMID 3905334. S2CID 23999344.
38. ^ Ariëns, Everardus J. (1986). "Stereochemistry: A source of problems in medicinal chemistry". Medicinal Research Reviews. 6 (4): 451–466\. doi:10.1002/med.2610060404. ISSN 0198-6325. PMID 3534485. S2CID 36115871.
39. ^ Baldwin, J.J.; Abrams, W. B (1988). Wainer, I.W.; Drayer, D.E. (eds.). Drug Stereochemistry, Analytical Methods and Pharmacology. New York: Marcel Dekker, New York. pp. 311–356.
40. ^ Williams, K. M (1990). Problems and wonder of chiral molecules. Budapest: Akademiai Kiado, Budapest. pp. 181–204\. ISBN 963-05-5881-5.
41. ^ Scott, Andrew K. (1993). "Stereoisomers and Drug Toxicity". Drug Safety. 8 (2): 149–159\. doi:10.2165/00002018-199308020-00005. ISSN 0114-5916. PMID 8452656. S2CID 20426452.
42. ^ Powell, J, R. (1988). Drug stereochemistry. Analytical methods and pharmacology. New York: Marcel Dekker, New York. pp. 245–270.`{{cite book}}`: CS1 maint: multiple names: authors list (link)
43. ^ Wright, Matthew R.; Jamali, Fakhreddin (1993). "Methods for the analysis of enantiomers of racemic drugs application to pharmacological and pharmacokinetic studies". Journal of Pharmacological and Toxicological Methods. 29 (1): 1–9\. doi:10.1016/1056-8719(93)90044-f. ISSN 1056-8719. PMID 8481555.
44. ^ Ariens, E.J (1989). Chiral Separations by HPLC. Chichester: Ellis Horwood, Chichester. pp. 31–68.
45. ^ White, Paul F.; Ham, Jay; Way, Walter L.; Trevor, Anthony (1980). "Pharmacology of Ketamine Isomers in Surgical Patients". Anesthesiology. 52 (3): 231–239\. doi:10.1097/00000542-198003000-00008. PMID 6989292. S2CID 38711416.
46. ^ Kohrs, Rainer; Durieux, Marcel E. (1998). "Ketamine". Anesthesia & Analgesia. 87 (5): 1186–1193\. doi:10.1213/00000539-199811000-00039. ISSN 0003-2999.
47. ^ Trevor, Anthony; Marietta, Michael; Pudwill, Charles; Way, Walter (1977). "Metabolism and Redistribution as Determinants of Duration of Effects of Ketamine in the Rat". Sixth International Congress of Pharmacology: abstracts. Elsevier. p. 583\. doi:10.1016/b978-0-08-021308-8.51428-9. ISBN 9780080213088.
48. ^ Hyneck, M (1990). Chirality in Drug Design and Synthesis. New York: Academic Press, New York. pp. 1–28.
49. ^ Cotzias, George C.; Van Woert, Melvin H.; Schiffer, Lewis M. (1967-02-16). "Aromatic Amino Acids and Modification of Parkinsonism". New England Journal of Medicine. 276 (7): 374–379\. doi:10.1056/nejm196702162760703. ISSN 0028-4793. PMID 5334614.
50. ^ Cotzias, George C.; Papavasiliou, Paul S.; Gellene, Rosemary (1969-02-13). "Modification of Parkinsonism — Chronic Treatment with L-Dopa". New England Journal of Medicine. 280 (7): 337–345\. doi:10.1056/nejm196902132800701. ISSN 0028-4793. PMID 4178641.
51. ^ Blessington, Bernard (1997). The impact of stereochemistry on drug development and use. New York: John Wiley & Sons, New York. pp. 235–261\. ISBN 0-471-59644-2.
52. ^ Kannappan, Valliappan. "Ethambutol – Chiralpedia". Retrieved 2022-08-27.
53. ^ Mellin, Gilbert W.; Katzenstein, Michael (1962-12-06). "The Saga of Thalidomide". New England Journal of Medicine. 267 (23): 1184–1193\. doi:10.1056/nejm196212062672305. ISSN 0028-4793. PMID 13934699.
54. ^ De Camp, Wilson H. (1989). "Letter to the editor". Chirality. 1 (2): 97–98\. doi:10.1002/chir.530010202. ISSN 0899-0042. PMID 2642047.
55. ^ "Thalidomide – Chiralpedia". 20 August 2022. Retrieved 2022-08-27.
56. ^ Stereochemical aspects of drug action and disposition. S. K. Branch, Michel Eichelbaum, Bernard Testa, Andrew Somogyi. Berlin: Springer. 2003. ISBN 978-3-540-41593-0. OCLC 52515592.`{{cite book}}`: CS1 maint: others (link)
57. ^ Eriksson, Tommy; Bjöurkman, Sven; Roth, Bodil; Fyge, Årsa; Höuglund, Peter (1995). "Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide: KINETICS OF THE ENANTIOMERS OF THALIDOMIDE". Chirality. 7 (1): 44–52\. doi:10.1002/chir.530070109. PMID 7702998.
58. ^ Eriksson, Tommy; Björkman, Sven; Höglund, Peter (2001). "Clinical pharmacology of thalidomide". European Journal of Clinical Pharmacology. 57 (5): 365–376\. doi:10.1007/s002280100320. ISSN 0031-6970. PMID 11599654. S2CID 7417671.
59. ^ Cornforth, R.H; Cornforth, J.W (1996). "How to be right and wrong". Croat. Chem. Acta. 69: 427–433.
60. ^ Ernest, L Eliel; Samuel H, Wilen (1990). "Misuse of homochiral". Chemical & Engineering News. 10: 2.
61. ^ Eliel, Ernest L. (1997). <428::aid-chir5>3.0.co;2-1 "Infelicitous stereochemical nomenclature". Chirality. 9 (5–6): 428–430\. doi:10.1002/(sici)1520-636x(1997)9:5/6<428::aid-chir5>3.0.co;2-1. ISSN 0899-0042.5–6&rft.pages=428-430&rft.date=1997&rft_id=info:doi/10.1002/(sici)1520-636x(1997)9:5/6<428::aid-chir5>3.0.co;2-1&rft.issn=0899-0042&rft.aulast=Eliel&rft.aufirst=Ernest+L.&rft_id=https://doi.org/10.1002/(sici)1520-636x(1997)9:5/6<428::aid-chir5>3.0.co;2-1&rfr_id=info:sid/en.wikipedia.org:Chiral+drugs" class="Z3988">
62. ^ Gal, Joseph (2013), Schurig, Volker (ed.), "Molecular Chirality: Language, History, and Significance", Differentiation of Enantiomers I, Topics in Current Chemistry, vol. 340, Cham: Springer International Publishing, pp. 1–20, doi:10.1007/128_2013_435, ISBN 978-3-319-03238-2, PMID 23666078, retrieved 2021-07-04
63. ^ Cayen, Mitchell N. (1991). "Racemic mixtures and single stereoisomers: Industrial concerns and issues in drug development". Chirality. 3 (2): 94–98\. doi:10.1002/chir.530030203. ISSN 0899-0042.
64. ^ Caldwell, John (1996). "Importance of stereospecific bionalytical monitoring in drug development". Journal of Chromatography A. 719 (1): 3–13\. doi:10.1016/0021-9673(95)00465-3. ISSN 0021-9673. PMID 8589835.
65. ^ Campbell, D.B. (1990). "The development of chiral drugs". Acta Pharm. Nord. 2 (3): 217–226\. PMID 2200432.
66. ^ Testa, Bernard; Carrupt, Pierre-Alain; Gal, Joseph (1993). "The so-called ?interconversion? of stereoisomeric drugs: An attempt at clarification". Chirality. 5 (3): 105–111\. doi:10.1002/chir.530050302. ISSN 0899-0042. PMID 8338720.
67. ^ Bhushan, R.; Tanwar, S. J. Chromatogr. A 2010, 1217, 1395–1398. (doi:10.1016/j.chroma.2009.12.071)
68. ^ Allenmark, Stig G. (1988). Chromatographic enantioseparation: methods and applications. Chichester: Ellis Horwood. pp. 27–40\. ISBN 9780131329454.

## External links

[edit]

* Media related to Chiral drugs at Wikimedia Commons

Authority control databases: National |

* Czech Republic

|